Evidence that remdesivir treatment reduces viral titers in patients with COVID-19 DOI Creative Commons
Simon Boyd,

Shivani Singh,

William HK Schilling

et al.

Antimicrobial Agents and Chemotherapy, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 7, 2024

Language: Английский

The relationship between viral clearance rates and disease progression in early symptomatic COVID-19: a systematic review and meta-regression analysis DOI Creative Commons
Shivani Singh, Simon Boyd, William HK Schilling

et al.

Journal of Antimicrobial Chemotherapy, Journal Year: 2024, Volume and Issue: 79(5), P. 935 - 945

Published: Feb. 5, 2024

Abstract Background Effective antiviral drugs accelerate viral clearance in acute COVID-19 infections; the relationship between accelerating and reducing severe clinical outcomes is unclear. Methods A systematic review was conducted of randomized controlled trials (RCTs) therapies early symptomatic COVID-19, where data were available. Treatment benefit defined clinically as relative risk hospitalization/death during follow-up (≥14 days), virologically SARS-CoV-2 rate ratio (VCRR). The VCRR rates intervention control arms. virological treatment effects assessed by mixed-effects meta-regression. Results From 57 potentially eligible RCTs, VCRRs derived for 44 (52 384 participants); 32 had ≥1 endpoint each arm. Overall, 9.7% (R2) variation explained with an estimated linear coefficient −0.92 (95% CI: −1.99 to 0.13; P = 0.08). However, this estimate highly sensitive inclusion recent very large PANORAMIC trial. Omitting outlier, half (R2 50.4%) [slope −1.47 CI −2.43 −0.51); 0.003], i.e. higher associated increased benefit. Conclusion determining studies vary greatly. As prohibitively sample sizes are now required show therapeutic assessments, a reasonable surrogate endpoint.

Language: Английский

Citations

10
Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV) DOI Creative Commons
Podjanee Jittamala, Simon Boyd, William HK Schilling

et al.

EClinicalMedicine, Journal Year: 2025, Volume and Issue: 80, P. 103036 - 103036

Published: Jan. 18, 2025

Language: Английский

Citations

0
ORCHESTRA Delphi Consensus: Diagnostic and Therapeutic Management of SARS-CoV-2 Infection in Solid Organ Transplant Recipients DOI Creative Commons

Beatrice Tazza,

Natascia Caroccia,

Alice Toschi

et al.

Clinical Microbiology and Infection, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

Citations

0
Efficacy of combined folic acid, cyanocobalamin, and pyridoxine hydrochloride therapy in the comprehensive management of pneumonia associated with COVID-19 DOI Creative Commons
I.Ya. Tseimakh, D.E. Bogachev,

A. Yu. Zhbanov

et al.

Bulletin physiology and pathology of respiration, Journal Year: 2025, Volume and Issue: 95, P. 40 - 57

Published: March 19, 2025

Aim. To evaluate the clinical efficacy and effect on serum homocysteine levels of combined folic acid, cyanocobalamin, pyridoxine hydrochloride therapy in comprehensive treatment pneumonia hospitalized patients with COVID-19. Materials methods. An open-label, prospective, comparative study included 75 moderate to severe associated COVID-19 confirmed by detection SARS-CoV-2 RNA respiratory tract. The main group consisted 28 who received micronutrient 30 mg/day acid plus cyanocobalamin addition standard treatment. comparison comprised 47 did not receive additional therapy. Charlson Comorbidity Index was 1.14 ± 0.93 0.47 0.69 (p ≤ 0.001). Disease severity before after assessed using NEWS, qSOFA, 4C Mortality, WHO Ordinal scales. Chest computed tomography (CT) performed. Laboratory parameters complete blood count, C-reactive protein (CRP), ferritin, lactate dehydrogenase (LDH), homocysteine, triglycerides, low- high-density lipoprotein cholesterol (LDL, HDL). Results. In group, elimination period achieved 7.2 3.4 days versus 15.6 6.3 < After therapy, disease decreased according qSOFA Mortality showed a reduction total volume from 32.0 (19.8–73.0)% 26.5 (11.8–50.8)% = 0.035) parenchymal consolidation 9.0 (0.0–37.3)% 2.0 (0.0–17.0)% 0.027). there no decrease lung involvement, area increased. These CT findings were reductions CRP, LDL levels. Multiple linear regression models demonstrated that administration combination shortened tract (regression coefficient β –8.648 1.781; p 0.001) contributed (β –13.492 4.834; 0.011), also linked baseline LDH 0.0235 0.00857; 0.008) patient age 0.167 0.0608; 0.008). Conclusion. use management COVID-19-associated is shorter upper tract, more pronounced severity, extent consolidation. effects coincide lower

Language: Английский

Citations

0
Identifying efficacious SARS-CoV-2 antivirals in a changing immune landscape DOI
Leo G. Visser

The Lancet Infectious Diseases, Journal Year: 2024, Volume and Issue: 24(9), P. 936 - 936

Published: April 24, 2024

Language: Английский

Citations

1
Evidence that remdesivir treatment reduces viral titers in patients with COVID-19 DOI Creative Commons
Simon Boyd,

Shivani Singh,

William HK Schilling

et al.

Antimicrobial Agents and Chemotherapy, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 7, 2024

Language: Английский

Citations

1